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Abstract
Background: Asthma exacerbations are common during pregnancy and associated with an increased risk of adverse
perinatal outcomes. Adjusting asthma treatment based on airway inflammation rather than symptoms reduces the
exacerbation rate by 50 %. The Breathing for Life Trial (BLT) will test whether this approach also improves perinatal outcomes.
Methods/design: BLT is a multicentre, parallel group, randomised controlled trial of asthma management guided by
fractional exhaled nitric oxide (FENO, a marker of eosinophilic airway inflammation) compared to usual care, with
prospective infant follow-up. Women with physician-diagnosed asthma, asthma symptoms and/or medication use in
the previous 12 months, who are 12–22 weeks gestation, will be eligible for inclusion. Women randomised to the
control group will have one clinical assessment of their asthma, including self-management education. Any treatment
changes will be made by their general practitioner. Women randomised to the intervention group will have clinical
assessments every 3–6 weeks during pregnancy, and asthma treatments will be adjusted every second visit based on
an algorithm which uses FENO to adjust inhaled corticosteroid (ICS) dose (increase in dose when FENO >29 parts per
billion (ppb), decrease in dose when FENO <19 ppb, and no change when FENO is between 19 and 29 ppb). A long
acting beta agonist (LABA) will be added when symptoms remain uncontrolled. Both the control and intervention
groups will report on exacerbations at a postpartum phone interview. The primary outcome is adverse perinatal
outcome (a composite measure including preterm birth, intrauterine growth restriction, neonatal hospitalisation at birth
or perinatal mortality), assessed from hospital records. Secondary outcomes will be each component of the primary
outcome, maternal exacerbations requiring medical intervention during pregnancy (both smokers and non-smokers),
and hospitalisation and emergency department presentation for wheeze, bronchiolitis or croup in the first 12 months
of infancy. Outcome assessment and statistical analysis of the primary outcome will be blinded. To detect a reduction
in adverse perinatal outcomes from 35 % to 26 %, 600 pregnant women with asthma per group are required.
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Discussion: This trial will provide evidence for the effectiveness of a FENO-based management strategy in improving
perinatal outcomes in pregnant women with asthma. If successful, this would improve the management of pregnant
women with asthma worldwide.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12613000202763.
Keywords: Asthma, Pregnancy, Perinatal, Exhaled nitric oxide, FENO, Asthma management, Exacerbation,
Antenatal care
Background
Asthma is a common chronic disease among pregnant
women, that affects more than 12 % of pregnant Austra-
lian women [1], and has an increasing prevalence world-
wide [2]. Up to 45 % of women with asthma have
exacerbations during pregnancy, requiring medical inter-
vention [3]; with the 20–30 % of women with asthma
who continue to smoke during pregnancy [3, 4], at an
even greater risk of a severe exacerbation [3]. Asthma it-
self, as well as exacerbations, moderate to severe asthma
[5, 6] and smoking [7] are significant risk factors for
poor perinatal outcomes, including pre-eclampsia, pre-
term delivery, low birth weight, small for gestational age,
neonatal hospitalisation and perinatal mortality [5, 8]. In
addition, oral corticosteroid use, a common treatment
for exacerbations, has been associated with preterm de-
livery [9, 10] and low birth weight [6]. Thus, an inter-
vention which reduces the rate of exacerbations during
pregnancy, may also improve perinatal outcomes, in
both smokers and non-smokers. Notably, in a meta-
analysis of prospective and retrospective cohort studies,
the risk for preterm delivery, preterm labour and neo-
natal hospitalisation among women with asthma was in-
creased in those without active asthma management,
while there was no increased risk in women with active
asthma management during pregnancy [5, 11]. This sug-
gests that the effect of maternal asthma on some peri-
natal outcomes may be modifiable with “active” asthma
management, and that asthma management during preg-
nancy, in both smokers and non-smokers, is important
and necessary for the health of the mother and her child.
Regular monitoring of asthma during pregnancy is rec-
ommended [12] for two main reasons: (i) typically, one
third of women experience an improvement, one third
have no change, and one third have a subjective worsen-
ing of their asthma while pregnant [13]; and (ii) these
changes are not easily predicted [14], which can compli-
cate management. Current practice is to adjust asthma
therapy following an assessment of symptoms and lung
function; however, these measures are not always reflect-
ive of airway inflammation [15], which is the target of
inhaled corticosteroid (ICS) therapy, suggesting that
treatment decisions may be inappropriate when based
on clinical assessment alone. Inflammation-guided ther-
apy, known as ‘inflammometry’ [16], is a novel alterna-
tive. This strategy has resulted in a significant reduction
in exacerbations in non-pregnant adults with asthma,
where the adjustment of ICS doses was informed by a
marker (or a surrogate marker [17]) of inflammation,
such as sputum eosinophils [18] or fractional exhaled ni-
tric oxide (FENO) [19]. Although FENO measurement is
supported by the American Thoracic Society for clinical
use to identify the need for ICS treatment, predict the
response to ICS, and to adjust ICS doses in non-
pregnant asthma [20], data is lacking to support its use
in pregnancy, with only one ‘inflammometry’ trial in
pregnancy published to date [21].
Our Managing Asthma in Pregnancy (MAP) Study
was the first randomised controlled trial (RCT) to inves-
tigate the use of FENO-guided management during
pregnancy and was conducted in 220 non-smoking
women [21]. In the intervention group, ICS dose was ad-
justed monthly based on the result of the FENO test,
which measures steroid sensitive inflammation, while
symptoms and lung function (assessed by the Asthma
Control Questionnaire, ACQ [22, 23]) were used to add
long acting beta agonist (LABA) when uncontrolled
symptoms remained. In the control group, monthly
treatment changes were made based on symptoms and
lung function (assessed by the ACQ) alone. There was a
significant 50 % reduction in the primary outcome, exac-
erbations requiring medical intervention, in the FENO
group, compared to the control group [21]. Moreover,
this trial found that exposure to oral and inhaled corti-
costeroids was significantly reduced in the FENO inter-
vention group [21]. While the trial was not powered for
neonatal or infant outcomes, the results also indicated a
reduction in neonatal intensive care unit (NICU) admis-
sions (7.6 % vs 16.5 %) and a reduced odds of recurrent
episodes of bronchiolitis (OR 0.08, 95 % CI [0.01, 0.62])
and recurrent croup (OR 0.12, 95 % CI [0.01, 0.99]) in
the first 12 months of life (parent reported), in the inter-
vention versus control group [24]. These promising re-
sults suggest that improving asthma management in
pregnancy may have long term benefits to childhood
health; however, these outcomes need to be further
Murphy et al. BMC Pregnancy and Childbirth  (2016) 16:111 Page 2 of 10
investigated in an adequately powered trial. The MAP
study ‘control’ group also received substantially en-
hanced care, in comparison to the management typically
provided by current practice, including monthly asthma
assessments and telephone follow-ups with a trained
asthma educator, provision of free asthma medications,
and monthly dose adjustments; thus, the efficacy of
FENO-based management is yet to be compared against
usual asthma care during pregnancy.
The effects of FENO-based asthma management during
pregnancy on perinatal and infant outcomes are yet to be
investigated in an adequately powered trial. In addition,
whether the intervention is effective in reducing exacerba-
tions in pregnant women who smoke is unknown. Exam-
ining the cost-effectiveness and acceptability of the
intervention in the clinical setting is warranted, in order
to support the future implementation of FENO-based
management into clinical practice.
Therefore, the primary aim of the Breathing for Life
Trial (BLT) is to assess whether FENO-guided manage-
ment of asthma during pregnancy reduces the rate of
adverse perinatal outcomes among non-smokers and
smokers, compared with usual best care. Secondary aims
of the trial are to assess whether, compared to usual best
care, FENO-guided management of asthma during preg-
nancy: (i) reduces exacerbations requiring medical inter-
vention among women who smoke; (ii) reduces the rate of
bronchiolitis, croup and wheeze leading to emergency
department presentation or hospitalisation in the first year
of infancy; (iv) is cost effective; and (iv) is acceptable to




BLT is a multicentre, parallel-group, RCT of FENO-guided
management in pregnant women with asthma compared to
usual care, with prospective infant follow-up for 12 months
(Figs. 1 and 2). Women will be randomly allocated to one




Pregnant women, aged 18 years or older, with physician
diagnosed asthma, symptoms of asthma or use of
asthma therapy (β2-agonist, ICS) in the past 12 months,
and who are 12–22 weeks gestation (supported by ultra-
sound or clinical obstetric assessment) at randomisation
will be enrolled in the trial. Exclusion criteria include
the inability to attend monthly study visits, inability to
perform manoeuvres required for spirometry or FENO,
drug or alcohol dependence, chronic oral corticosteroid
use for more than 14 consecutive days in the past three
months, chronic lung disease other than asthma, or con-
comitant chronic illness which may affect participation
(to be decided with medical investigator(s) on a case-by-
case basis).
Setting
Eligible women with asthma will be recruited from public
hospital antenatal clinics prior to 23 completed weeks
gestation. This trial is being conducted within the ante-
natal clinic at six sites across Australia: the Royal Brisbane
and Women’s Hospital (QLD), the Royal North Shore
Fig. 1 Participant flow diagram
Murphy et al. BMC Pregnancy and Childbirth  (2016) 16:111 Page 3 of 10
Hospital (Sydney, NSW), the Royal Hospital for Women
Randwick (Sydney, NSW), Nepean Hospital (Penrith,
NSW), The Canberra Hospital (Canberra, ACT) and the
John Hunter Hospital (Newcastle, NSW, central site). If
recruitment is slower than expected or difficulty is en-
countered with the aforementioned sites, other sites may
be sought.
All women will provide written informed consent prior
to participation.
Intervention
Usual best care control group
Women randomised to the usual care (control) group will
have one study visit of approximately 30 min at baseline
with a trained research nurse or midwife. At this visit,
patient demographics and characteristics (including ma-
ternal height, weight and ethnicity), asthma history and
current medications will be collected. Asthma symptoms,
triggers and self-management skills will be assessed; brief
asthma education, correction of inhaler technique (as re-
quired), and written information (a pamphlet on asthma
and pregnancy, available from Asthma Australia [25]) will
be provided. Lung function will be assessed by spirometry,
using the EasyOne Spirometer (Niche Medical, Sydney,
Australia). Maternal smoking will be self-reported and
confirmed by exhaled carbon monoxide (ECO) measure-
ment (piCO Smokerlyzer Breath CO Monitor, Bedfont,
UK; ≥10 parts per million (ppm) will be considered
Fig. 2 Breathing for Life Trial Study Design
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current smokers) and advice on smoking cessation pro-
vided as appropriate, with a referral to the Quitline for fur-
ther assistance. Health care providers (general practitioner
(GP), midwife and respiratory physician as applicable) will
be informed of the woman’s participation in the trial. No
medications will be provided by the trial for the control
group; the woman’s asthma therapy will continue to be
managed by their physician. All women will continue with
standard antenatal care visits, and will receive a phone call
within six weeks post-partum to enquire about any
asthma-related health events (exacerbations) and adverse
health events.
Treatment
Women randomised to the FENO-based management
intervention will receive usual best care (as described
above) plus monthly follow-up (three to six weekly) with
the research nurse or midwife coinciding with their regu-
lar antenatal appointments, until delivery. Women with-
out a written asthma action plan will be provided with
one. At each visit, FENO will be measured using the port-
able NIOX MINO or NIOX VERO analyser (Aerocrine,
Solna, Sweden), along with ECO measurement and spir-
ometry. Asthma assessments will be conducted, including
completion of the ACQ [22], a 7-item validated question-
naire which covers symptoms (6 items) and lung function
(1 item), with scores >1.5 indicating uncontrolled asthma
[23]. Results from the ACQ and FENO measurement will
be entered into a predetermined algorithm (using an excel
spreadsheet and/or specially-designed application for
personal mobile devices), which will be used to assign any
pharmaceutical treatment changes (Table 1). Starting at
the first visit and every second visit thereafter, mainten-
ance treatment changes will be made based on the results
of this algorithm. When women are taking additional
treatment for an exacerbation, no alterations will be made
until they return to their maintenance dose. Women who
self-report cigarette smoking in the previous week, or have
ECO ≥10 ppm, will be considered current smokers for the
purposes of applying the treatment algorithm. Required
medication will be supplied by the hospital pharmacy at
no cost to the participant. Asthma medications will be al-
tered in a two-stage process: (i) assess FENO (eosinophilic
inflammation) and adjust anti-inflammatory ICS; and (ii)
assess symptoms and lung function (using the ACQ) and
adjust long acting β2-agonists (LABA) (Table 1). When
FENO is elevated (>29 ppb in non-smokers), the ICS dose
will be increased by one dose step. When FENO is low
(<19 ppb in non-smokers), the ICS dose will be decreased
by one dose step. When FENO is in the mid-range (19–
29 ppb for non-smokers), the ICS dose will not be chan-
ged. If the ACQ score is >1.5, that is, uncontrolled asthma,
LABA will be added. Women using ICS or ICS/LABA
combinations will have a treatment recommendation pro-
vided as an equivalent dose of budesonide (Pulmicort) or
budesonide/e-formoterol (Symbicort). Budesonide has a
category A safety rating for use in pregnancy [12, 26].
Women will use salbutamol (category A), as needed, for
reliever medication. Exacerbation management will not be
part of the trial. However, subjects will be provided with
the phone contact details of the study nurse or midwife,
and, if requesting advice during exacerbations, will be
recommended to attend their primary care practitioner, or
attend an emergency department.
Additional methods
Infant follow-up
A validated parent-completed questionnaire [27] which
examines patterns of respiratory illnesses and symptoms
(such as croup, bronchiolitis, cough, colds and wheeze),
family medical history, food intake, immunisations and
household information will be mailed to consenting
mothers from BLT with living children at 6 and
12 months of age. We have previously used this ques-
tionnaire to obtain data from the MAP study infants
[24]. Medical records will also be used to assess emer-
gency department presentations and hospitalisations for
wheeze, bronchiolitis or croup.
Cost-effectiveness analysis
The interventions will be evaluated using the Asses-
sing Cost-Effectiveness in Prevention (ACE-Prevention)
methodology [28]. These methods are international best-
practice for cost-effectiveness analysis and include: the
adoption of a health system perspective; transparent and
scientific methods to identify, measure and value both
Table 1 FENO Algorithm cut-points and dose changes based on FENO measurement on NIOX MINO and results from the Asthma
Control Questionnaire (ACQ)
Non-smokers NIOX MINO cut-points Smokers NIOX MINO cut-points Symptoms [ACQ] ICS dose change β2-agonist dose change
>29 ppb >22 ppb N/A ↑ ICS x 1 step No change
19–29 14–22 <=1.5 No change No change
19–29 14–22 >1.5 No change ↑ LABA 1 step
<19 <14 <=1.5 ↓ ICS x 1 step No change
<19 <14 >1.5 ↓ ICS x 1 step ↑ LABA 1 step
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costs and outcomes from the trial; modelling and uncer-
tainty testing of epidemiological and costing input param-
eters; and interpretation of results within a broader
decision-making framework. Costing data will be collected
using medical records and the measure of effect will be
derived from the trial’s primary outcome.
Acceptance of the intervention
The acceptability of the FENO-guided management ap-
proach will be evaluated using questionnaires and quali-
tative interviews with pregnant women, midwives and
antenatal clinic staff, to examine a range of clinical and
patient perspectives. Face-to-face interviews at the home
or in the antenatal clinic will be conducted with 15–20
pregnant women per group at 34–36 weeks gestation.
Interviews will be analysed using qualitative descriptive
methodology [29]. A purposive sample of women will be
selected from different hospital sites, and from a range of
backgrounds (smokers/non-smokers, severe/less severe
asthma, high/low education). Interviews will also be con-
ducted with the research nurse, a senior midwife and the
nursing unit manager/other antenatal clinic staff to investi-
gate specific issues related to a sustainable implementation
of this intervention in each clinic (18–20 interviews total).
Interviews will be digitally recorded and transcribed verba-
tim, and analysed thematically.
Outcomes
Primary outcome
The primary outcome is the proportion of pregnancies
with an adverse perinatal outcome, defined as: preterm
birth (delivery at <37 weeks gestational age); intrauterine
growth restriction (IUGR), defined as a birth weight
<10th centile for gestational age (based on a dataset of
12,500 Australian births, calculated using the Gestation
network calculators available online at http://gestation.-
net); perinatal mortality (stillbirth or neonatal death
within the first 28 days of life); or neonatal hospitalisa-
tion at birth. These details will be determined by review
of the hospital medical records and/or data extraction
from the hospital obstetric/perinatal database (outcome
assessor will be blinded to group allocation).
Secondary outcomes
Secondary outcomes for the trial are: (i) preterm birth,
as previously defined; (ii) IUGR, as previously defined;
(iii) perinatal mortality, as previously defined; (iv) neo-
natal hospitalisation, including number of days of admis-
sion; (v) mean birth weight; (vi) maternal hospitalisation
for asthma, including number of days of admission; and
(vii) in women who smoke, maternal exacerbations re-
quiring medical intervention, defined as hospitalisation,
emergency department presentation or a course of oral
corticosteroids (severe exacerbation) or an unscheduled
doctor’s visit (moderate exacerbations). These outcomes
will be determined by review of the woman’s hospital
medical records and/or data extraction from the hospital
obstetric/perinatal database, and participant report at a
postpartum telephone interview. The type of preterm
birth will also be recorded (spontaneous labour, preterm
rupture of membranes, or indicated preterm birth) [30].
Additional outcomes
Infant follow-up
The outcome will be the proportion of subjects with se-
vere respiratory illnesses (bronchiolitis, croup, wheezing)
in the first year of life, defined as those that required an
emergency department presentation or hospitalisation.
This information will be determined from the parental
questionnaires at 6 and 12 months and from medical re-
cords at each site.
Cost-effectiveness
The cost-effectiveness analysis will adopt adverse peri-
natal events as the primary outcome, consistent with the
clinical trial.
Acceptance of the intervention
A qualitative description of the acceptability of the trial
by a sub-sample of participants and participating ante-
natal clinic and staff will be collected.
Sample size
Primary outcome
Previous data from pregnant smokers (n = 47) and non-
smokers (n = 211) with asthma, demonstrated that 35.3 %
of pregnancies managed by a clinical guidelines-based al-
gorithm had an adverse perinatal outcome (preterm deliv-
ery, IUGR [birth weight < 10th centile], stillbirth, or
neonatal intensive care [NICU] admission) compared to
26.2 % of those managed by a FENO-based algorithm (un-
published data). To demonstrate this group difference in
the proportion of adverse perinatal outcomes (preterm
birth, IUGR, neonatal hospitalisation, or perinatal mortal-
ity), with 90 % power and alpha of 0.05, between FENO-
based management and usual best care, we require 539
women per group. Allowing for 10 % loss to follow-up, we
aim to recruit 600 women per group.
Secondary outcome
We anticipate that a sample size of 600 women per
group will include approximately 120 current smokers
per group (20 %). This will provide 99 % power to detect
a 50 % reduction in the proportion of women with exac-
erbations requiring medical intervention among smokers
(as demonstrated in non-smokers in our previous RCT
[21]). This represents a reduction from 52 % of women
having exacerbations [3] to 26 %.
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Randomisation/treatment allocation
Sequence generation
The randomisation sequence will be computer generated
using an online system accessed via a secure website, de-
veloped specifically for BLT by Hunter Medical Research
Institute (Newcastle, NSW). Eligible consenting women
will be randomly allocated to the FENO-based manage-
ment or usual care groups using variable block sizes of 4
and 6, stratified by site and baseline self-reported smok-
ing status.
Allocation concealment
The online system will not allow randomisation of a par-
ticipant unless all criteria are met and will not allow un-
registered withdrawal after randomisation. This system
assigns each participant a unique randomisation number.
Implementation
The research nurse/midwife at the site will enrol the
participants and enter their inclusion criteria, site and
smoking status into the online system.
Blinding
Given the nature of the intervention, it is not possible to
blind participating women, the research staff or the par-
ticipants’ healthcare providers, to their group allocation.
However, the primary and secondary outcomes will be
assessed by a review of medical records and data ex-
tracted from hospital databases by a researcher blinded
to group allocation; there will be no involvement of re-
search staff in the clinical management of pregnancy,
labour and delivery; and analysis of the primary outcome
will be performed by a statistician blinded to group
allocation.
Statistical methods
Data will be analysed on an intention-to-treat basis,
using two-sided tests with p < 0.05 considered statisti-
cally significant.
Primary outcome
The proportion of subjects with an adverse perinatal
outcome will be compared between groups using logistic
regression. The outcome in the model will be adverse
perinatal outcome (yes/no), the main predictor of inter-
est will be management group and study centre will be
included as a covariate, due to potential differences in
socioeconomic status, environmental exposures and
management practices.
Secondary outcomes
Mean birth weight will be compared between groups by
linear regression, while the proportion of subjects with
preterm birth, IUGR, perinatal mortality or neonatal
hospitalisation will be compared using logistic regres-
sion, adjusted for study centre. The proportion of
women requiring a hospitalisation for asthma and the
proportion of smokers with an asthma exacerbation re-
quiring medical intervention, will be compared between
groups using logistic regression, adjusted for site.
Additional outcomes
Infant follow-up
The proportion of infants with severe respiratory ill-
nesses requiring an emergency department visit or hos-
pitalisation in the first year of life will be compared
between the groups using logistic regression, adjusted
for site, and other potential confounders.
Cost-effectiveness
The analysis will model costs and outcomes over a ten
year period discounting future costs and health out-
comes at a rate of 3 % per year. The costs and health
outcomes are summed to determine the incremental
cost-effectiveness ratio. Monte Carlo analysis is used to
derive 95 % uncertainty intervals. The results of the
cost-effectiveness analysis will be considered in the con-
text of other decision making criteria including: strength
of evidence, capacity of the intervention to reduce
inequity, acceptability to stakeholders, feasibility, sus-
tainability and potential for other consequences. A sensi-
tivity analysis will be conducted on parameters with
uncertain values.
Acceptance of the intervention
Thematic analysis will be used to examine acceptability
and barriers to implementation in the antenatal clinic.
Data monitoring and safety board
An independent Data Monitoring and Safety Board
(DSMB) will be established with terms of reference.
Discussion
Women with asthma are at an increased risk of adverse
perinatal outcomes. We propose that providing im-
proved antenatal care, which incorporates optimum
asthma management using a FENO-based approach, will
be effective in reducing these risks among this popula-
tion of women, with positive consequences for infant
health both in the short term and long term. This trial
will provide the first evidence as to whether the
provision of FENO-based management, as opposed to
current best care, can significantly reduce the rate of ad-
verse perinatal outcomes, that is, preterm delivery,
IUGR, perinatal mortality or neonatal hospitalisation. If
proven successful, this intervention would have pro-
found implications for the health of pregnant women
with asthma and their offspring. Specifically, if severe
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respiratory illnesses such as bronchiolitis were reduced
in infancy, then FENO-based asthma management in
pregnancy has potential as a primary prevention strategy
for childhood asthma, representing a significant break-
through in asthma research. Furthermore, if successful
and cost-effective, this intervention could be imple-
mented into primary care settings such as the antenatal
clinic and potentially reduce the burden on the health
care system.
The trial will be powered to detect a significant differ-
ence in the proportion of smoking mothers who have
exacerbations requiring medical intervention. This is an
important objective for the following reasons: (i) preg-
nant women with asthma are more likely to smoke than
pregnant women without asthma [4]; (ii) compared with
non-smokers, asthmatic women who smoke are at an in-
creased risk of poor perinatal outcomes from the com-
bined effects of smoking, asthma and severe asthma
exacerbations [3]; and (iii) the quit rate for smoking in
pregnancy is surprisingly low (6–10 %) in Australia, des-
pite best practice [31]. Therefore, an intervention that
could reduce the rate of asthma exacerbations in women
who smoke during pregnancy would have a significant
impact on the management of a group of high-risk
women.
The Breathing for Life Trial builds upon our pre-
vious trial, which successfully demonstrated a sig-
nificant reduction in maternal exacerbations using
FENO-based management. BLT simplifies the FENO-
based management approach used in the previous
trial in several ways: (i) the number of drug formula-
tions available will be reduced; (ii) the FENO algo-
rithm results will be generated electronically; (iii)
asthma assessments will be aligned with antenatal
clinic appointments; and (iv) fewer treatment changes
will be made (every two months instead of monthly).
In addition, we will measure FENO using the NIOX
MINO (or NIOX VERO) electrochemical analyser, an
instrument which is practical for use in the antenatal
clinic setting, where space and time are limited. It is
small and portable, relatively inexpensive and easy to
use (no calibration required) and obtains a measure-
ment in less than two minutes (Table 2).
The implementation of the approach in a public hos-
pital antenatal clinic was not previously investigated, nor
was the cost-effectiveness of the intervention. In this
trial, we have chosen centres across NSW, ACT and
Queensland which differ in location (capital city, re-
gional, tertiary/non-tertiary hospital), the proportion of
smoking and obese women, maternal age and education
attainment, severity of asthma, ethnic backgrounds and
socioeconomic status. Therefore, it is anticipated that
the intervention will be applicable to the general
population.
As part of this trial, we have included a cost-
effectiveness analysis of the primary outcome, that is,
adverse perinatal outcomes. This will provide policy
relevant information that can be used to determine
the resources required for wider implementation of
the intervention. In addition, a qualitative assessment
of the acceptability of the intervention to both
mothers and the antenatal clinic staff will be per-
formed. Therefore, this novel trial will address poten-
tial obstacles to implementation in standard practice,
including issues of cost and feasibility, generalisability,
and effectiveness, compared to usual care.
We acknowledge that our control group may not be
reflective of typical usual care; however, it was deemed
unethical to deny a certain level of care to women with
asthma during pregnancy. Therefore, the control group
will be provided with minimal assessment and education
with a trained nurse/asthma educator at the first visit
only, that is, self-management skills, knowledge and
medication use will be assessed, with brief asthma edu-
cation, correction of inhaler technique (as required), and
written information provided. Of note, this is a reduc-
tion in the level of care given to the ‘control’ group com-
pared to the MAP trial; thus, this minimal level of care
is unlikely to affect group differences in our chosen
outcomes.
In conclusion, the Breathing for Life Trial is designed
to test an approach which is simple, effective in improving
maternal asthma during pregnancy (both for smokers and
non-smokers), whilst also being beneficial to the infant,
cost-effective, accessible and acceptable to women attend-
ing antenatal clinics.
Ethics approval and consent to participate
Ethics approval was obtained for the Breathing for Life
Trial at all centres through the Hunter New England
Human Research Ethics Committee (Reference Number
12/10/17/3.04, NSW HREC Reference No: HREC/12/
HNE/357). Site-specific approval will be attained for all
participating sites prior to active recruitment. Site-specific
approvals have been obtained for the co-ordinating site at
the John Hunter Hospital (SSA Reference No: SSA/12/
HNE/393), and five external sites: Royal Brisbane and
Women’s Hospital (SSA/14/QRBW/358), the Royal
Hospital for Women Randwick (SSA 14/G/333), Nepean
Hospital (SSA Reference No: SSA/14/NEPEAN/84), Royal
North Shore Hospital (SSA/15/HAWKE/142) and The
Canberra Hospital (ACT Health Human Research Ethics
Committee, ETH.11.15.232). Ethics approvals have also
been registered with the University of Newcastle (Refer-
ence No: H-2012-0422) and University of Queensland
(Approval No: 2014000807) Human Ethics Committees.
All participants will provide written informed consent
prior to participation.
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